TY - JUR A2 - Sorrenti，Valeria Au - 夏，清奥 - 韩，桃奥 - 杨，平华AU - 王，汝宇Au - Li，恒宇奥义，金奥 - 周，XINFENG PY - 2019 DA - 2019 /12/01 TI - MicroRNA-28-5P通过IGF-1途径SP - 8734362 VL - 2019 AB - 背景。MicroRNA（miRNA）在癌症干细胞（CSC）的调节中起着关键作用。然而，miRNA在肝脏CSC中的作用尚未完全阐明。 方法。使用实时PCR检测肝癌干细胞（CSC）中miR-miR-28-5p的表达。miR-28-5p对体内和体外体内的肝脏CSC扩增的影响。在患者衍生的异种移植物（PDX）中进一步评估了HCC中MiR-28-5P表达和索拉非尼的益处之间的相关性。 结果。我们的数据显示MiR-28-5P在分类的EPCAM-和CD24阳性肝CSC中下调。生物功能调查显示，敲低miR-28-5p促进肝脏CSC自我更新和肿瘤发生。始终如一地，miR-28-5p过表达抑制肝CSC的自我更新和肿瘤率。Mechanistically, we found that insulin-like growth factor-1 (IGF-1) was a direct target of miR-28-5p in liver CSCs, and the effects of miR-28-5p on liver CSC’s self-renewal and tumorigenesis were dependent on IGF-1. The correlation between miR-28-5p and IGF-1 was confirmed in human HCC tissues. Furthermore, the miR-28-5p knockdown HCC cells were more sensitive to sorafenib treatment. Analysis of patient-derived xenografts (PDXs) further demonstrated that the miR-28-5p may predict sorafenib benefits in HCC patients. 结论。我们的研究结果揭示了miR-28-5p在肝脏CSC膨胀和索拉非尼反应中的关键作用，渲染MIR-28-5P对HCC的最佳治疗靶标。SN - 1687-966X UR - HTTPS://Doi.org/10.1155/2019/8734362 Do - 10.1155 / 2019/8734362 JF - 干细胞国际PB - Hindawi Kw - ER -